gen1053
mAbexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 4, 2022 (NCT05435339)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- CD27 antigenINHIBITOR
CD27 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05435339 | Phase 1/Phase 2 (Phase 2) | Oct 4, 2022 | Biontech, Genmab |
Showing 1 of 1 trials
Page 1 / 1